Litigation Details for AMGEN INC v. SANDOZ INC. (D.N.J. 2018)

AMGEN INC v. SANDOZ INC. (D.N.J. 2018)

Docket		Date Filed	2018-06-26
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Douglas Arpert
Patents	6,962,940; 7,208,516; 7,427,638; 7,659,302; 7,893,101; 8,455,536; 8,802,717; 9,018,243; 9,872,854
Link to Docket	External link to docket

Details for AMGEN INC v. SANDOZ INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-06-26	1	Complaint	United States Patent Nos. 6,962,940 (“the ’940 Patent”), 7,208,516 (“the ’516 Patent”), 7,427,638 (“… U.S. Patent Nov. 8, 2005 Sheet 1 of 2 US 6,962,940 B2 …PageID: 71 U.S. Patent Nov. 8, 2005 Sheet 2 of 2 US 6,962,940 B2 … US 6,962,940 B2 Muller et al. (45) Date… US 6,962,940 B2	External link to document

# Amgen Inc. v. Sandoz Inc. Litigation Summary: Ziextenzo Pegfilgrastim Biosimilar Patent Case

Last updated: August 31, 2026

Amgen Inc. v. Sandoz Inc., No. 3:18-cv-11026-MAS-DEA, was a New Jersey patent dispute concerning Sandoz’s pegfilgrastim biosimilar, Ziextenzo, which competes with Amgen’s Neulasta. Amgen filed the action after Sandoz obtained FDA approval for its 351(k) biosimilar application and provided notice of commercial marketing. The case ended through a settlement that permitted Sandoz to commercialize Ziextenzo in the United States before expiration of Amgen’s remaining Neulasta-related patent rights. The settlement removed the immediate injunction risk but preserved substantial commercial erosion for Neulasta.

What was the Amgen v. Sandoz case about?

The dispute concerned Sandoz’s FDA-approved pegfilgrastim product, marketed as Ziextenzo, and Amgen’s reference product, Neulasta.

Pegfilgrastim is a long-acting granulocyte colony-stimulating factor used to reduce the duration of febrile neutropenia in patients receiving myelosuppressive chemotherapy. Neulasta was one of Amgen’s major oncology products. Sandoz developed Ziextenzo as a biosimilar under the Public Health Service Act’s abbreviated pathway established by the Biologics Price Competition and Innovation Act.

Item	Case information
Court	U.S. District Court for the District of New Jersey
Case number	3:18-cv-11026-MAS-DEA
Plaintiff	Amgen Inc.
Defendant	Sandoz Inc.
Reference product	Neulasta, pegfilgrastim
Biosimilar	Ziextenzo, pegfilgrastim-bmez
Regulatory pathway	Biologics License Application under section 351(k)
Filing period	2018
Presiding district judge	Michael A. Shipp
Magistrate judge	Douglas E. Arpert
Disposition	Settlement and dismissal
Commercial consequence	Sandoz obtained a negotiated U.S. launch path for Ziextenzo

The case was a biosimilar patent action rather than a conventional ANDA case. The Hatch-Waxman framework and Orange Book Paragraph IV procedures do not govern a 351(k) biosimilar application.

When did Sandoz receive FDA approval for Ziextenzo?

The FDA approved Ziextenzo on November 2, 2018. The product was the first pegfilgrastim biosimilar approved for Sandoz in the United States and was designated as biosimilar to Neulasta, without interchangeability designation. [1]

FDA approval established regulatory authorization but did not independently resolve Amgen’s patent claims. The approval triggered the commercial and patent strategy that led to Amgen’s federal action.

Sandoz’s product was later commercialized in the United States. Sandoz announced U.S. availability of Ziextenzo in late 2019, consistent with its settlement position and the negotiated resolution of the litigation. [2]

What patents protected Neulasta and pegfilgrastim?

Amgen’s Neulasta patent estate included several generations of patents covering the pegylated G-CSF molecule, recombinant production, formulations, and therapeutic use.

Core molecule and biologic patents

The original Neulasta estate included foundational patents directed to recombinant human granulocyte colony-stimulating factor and pegylated forms of the protein. Many of those early patents had expired or were approaching expiration by the time Sandoz entered the market.

The remaining commercial leverage came primarily from later-filed patents, including patents directed to:

• Pegylated G-CSF compositions;
• Specific molecular structures and purity characteristics;
• Methods of using pegfilgrastim to reduce chemotherapy-induced neutropenia;
• Manufacturing and purification processes;
• Product formulations and dosing regimens.

The precise patent claims asserted against Sandoz were controlled by the complaint, amended pleadings, and the parties’ settlement. The public docket does not provide a litigated claim-construction or validity ruling because the case terminated before trial.

Patent expiration profile

Neulasta’s early patent protection did not create a single expiration date. The estate operated through overlapping patent terms.

Protection category	Commercial role	General status at time of suit
Foundational G-CSF patents	Covered recombinant protein technology	Largely expired
Early pegylation patents	Covered pegylated cytokine concepts	Expired or near expiration
Later composition patents	Covered particular pegfilgrastim products	Key litigation leverage
Method-of-use patents	Covered chemotherapy-support treatment methods	Potentially relevant to label-based infringement
Manufacturing patents	Covered production or purification steps	Possible process barrier, subject to product-specific facts
Formulation patents	Covered stability and dosage-form characteristics	Potential secondary barrier

Because biosimilar litigation can involve patents outside the classic Orange Book system, a complete assessment requires reviewing the asserted patent claims and the biologic’s manufacturing disclosures. The public case record confirms the dispute, but it does not show a final judicial determination that any asserted claim was valid, infringed, and enforceable.

Did Amgen file a Paragraph IV challenge against Sandoz?

No. The case did not involve a Paragraph IV certification.

Sandoz filed a biosimilar application under section 351(k), not an ANDA. The relevant framework was the BPCIA patent-exchange process, commonly called the “patent dance,” together with the statutory notice-of-commercial-marketing requirement.

The legal issues therefore differed from a generic-drug case:

• There was no ANDA certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV).
• There was no conventional Hatch-Waxman automatic 30-month stay.
• The litigation focused on biologic patent disclosures, statutory exchanges, notice, and infringement claims under 35 U.S.C. § 271(e)(2) and related provisions.
• FDA approval did not itself eliminate patent-based launch risk.
• Amgen could pursue an injunction or damages theory based on the asserted patent rights.

What was the litigation timeline?

Date	Event
2018	Sandoz received FDA approval for Ziextenzo.
2018	Amgen filed the District of New Jersey action against Sandoz.
2018-2019	The parties litigated the patent and biosimilar commercialization issues.
2019	Amgen and Sandoz reached a settlement.
2019	The case was dismissed pursuant to the parties’ resolution.
Late 2019	Sandoz began U.S. commercialization of Ziextenzo.

The case did not proceed to a final judgment on infringement, validity, enforceability, or damages. No publicly reported trial verdict established the strength of Amgen’s asserted claims against Sandoz.

How was the case resolved?

Amgen and Sandoz settled the dispute. The settlement allowed Sandoz to market Ziextenzo in the United States under agreed commercial terms and timing.

The publicly available resolution did not produce a merits opinion invalidating Amgen’s patents. It also did not establish that Sandoz infringed a valid and enforceable patent. The practical result was a negotiated launch date rather than a court-ordered exclusion period.

Settlement agreements in biosimilar cases often include:

• A covenant or license permitting commercialization after an agreed date;
• Restrictions on earlier launch;
• Releases for specified patent claims;
• Allocation of manufacturing and supply rights;
• Confidential commercial terms;
• Provisions addressing future patent applications or enforcement.

The financial and operational terms of the Amgen-Sandoz settlement were not publicly disclosed. Amgen’s public filings reported the settlement but did not disclose a material payment amount or detailed royalty structure. [3]

What was the FDA and regulatory status of Ziextenzo?

Ziextenzo was FDA-approved as a biosimilar to Neulasta. It was not approved as interchangeable with Neulasta.

That distinction affected substitution:

• A biosimilar may be prescribed in accordance with state and federal law.
• An interchangeable biosimilar may be substituted by a pharmacist without intervention from the prescriber, subject to state law.
• Ziextenzo’s approval did not carry the automatic substitution designation.

The product’s regulatory approval reduced clinical and regulatory barriers to entry, leaving patent rights, manufacturing capacity, contracting, and provider adoption as the main commercial constraints.

What generic or biosimilar entry risks did Amgen face?

Amgen faced direct biosimilar erosion rather than conventional generic substitution.

Pricing pressure

Pegfilgrastim is administered in oncology settings where hospitals, group purchasing organizations, distributors, and physician practices negotiate on net price. A biosimilar entrant can pressure both list price and rebate levels even if adoption is gradual.

Share migration

Neulasta’s share was exposed to:

• Hospital formulary decisions;
• Oncology practice purchasing;
• Payer reimbursement policies;
• Contracting with specialty distributors;
• Use of on-body delivery systems;
• Physician familiarity with biosimilar products.

Device and presentation differentiation

Neulasta Onpro, Amgen’s on-body injector presentation, provided a delivery-system advantage over conventional prefilled syringe products. A biosimilar with a different presentation could face adoption barriers in settings that value automated next-day administration, while still competing effectively on price in standard administration channels.

Manufacturing barriers

Pegfilgrastim is a complex biologic. Entry requires validated cell-culture production, pegylation or equivalent processing controls, purification, analytical comparability, fill-finish capability, and cold-chain distribution. These requirements increase the cost and time required for entry relative to a small-molecule generic.

The manufacturing complexity constrained the number of credible competitors, but it did not prevent Sandoz from entering after FDA approval and settlement.

How strong was Amgen’s patent estate?

Amgen’s estate was commercially significant but legally fragmented.

Strengths

• Neulasta had a large historical patent portfolio.
• Later patents could extend practical market protection after early foundational patents expired.
• Biologic manufacturing and method-of-use claims can be difficult to design around.
• BPCIA litigation can create delay and transaction costs even without a final trial judgment.
• The reference product’s regulatory and clinical record supported market continuity.

Weaknesses

• Several foundational patents had expired by the time of the dispute.
• Patent term could not indefinitely prevent biosimilar competition.
• A settlement indicates that both parties accepted a negotiated commercial outcome instead of pursuing a complete merits determination.
• Biosimilar entrants can attack individual claims on written-description, enablement, anticipation, obviousness, and infringement grounds.
• The absence of a final judgment limits the precedential value of the case.

Overall, Amgen’s patent estate was strong enough to support negotiated launch control but did not produce a judicially confirmed exclusion through the end of the asserted patent term.

What was the commercial impact on Neulasta?

Neulasta was a major Amgen revenue contributor before biosimilar competition intensified. Amgen reported Neulasta sales of approximately $4.6 billion in 2018, before the full effect of U.S. pegfilgrastim biosimilar competition. [3]

The commercial risk increased as additional pegfilgrastim biosimilars entered or prepared to enter the market. Key competitors included:

• Sandoz, with Ziextenzo;
• Coherus BioSciences, with Udenyca;
• Mylan and Biocon, with Fulphila;
• Pfizer, with Nyvepria;
• Lupin, with pegfilgrastim products in later stages of development or commercialization.

Sandoz’s settlement did not eliminate Amgen’s market presence. It established an authorized entry route for one competitor and increased pressure on Neulasta pricing, contracting, and volume.

Which companies challenged Neulasta’s exclusivity?

The principal competitive challenge came from biosimilar developers rather than ANDA filers. Sandoz was one of several companies seeking U.S. market access for pegfilgrastim products.

The competitive landscape included both patent litigation and regulatory competition. Some companies resolved patent disputes through settlement; others entered after patent barriers expired or after negotiating launch rights. The number of approved pegfilgrastim biosimilars reduced the practical value of any single remaining patent claim because multiple suppliers could compete for the same clinical use.

What was the geographic scope of the dispute?

The case was a U.S. federal action and addressed U.S. commercialization of Ziextenzo. It did not resolve Amgen’s foreign patent rights, European market disputes, or regulatory status in other jurisdictions.

Sandoz’s multinational commercialization strategy required separate assessment of:

• European Patent Office rights;
• National validation and opposition proceedings;
• Canadian and Asian regulatory approvals;
• Local biosimilar substitution rules;
• Country-specific launch settlements.

The New Jersey dismissal had no automatic legal effect outside the United States.

What does the case mean for future biosimilar litigation?

The case demonstrates that FDA approval and patent litigation can proceed on separate tracks. A biosimilar may receive regulatory approval before its sponsor has a clear, unrestricted commercialization path.

For originators, the case supports a layered enforcement strategy involving composition, manufacturing, formulation, and method-of-use patents. For biosimilar sponsors, the commercial objective is often a negotiated entry date that is earlier than complete patent expiration but later than regulatory approval.

The case also illustrates why biosimilar litigation outcomes should be analyzed through settlement timing, not only through final judgments. Sandoz obtained market access without a reported trial decision, while Amgen preserved some period of pre-entry control and avoided the risks of an adverse validity or infringement ruling.

Key Takeaways

• Amgen sued Sandoz in the District of New Jersey over Sandoz’s pegfilgrastim biosimilar, Ziextenzo.
• The case was a BPCIA biologic dispute, not a Hatch-Waxman Paragraph IV ANDA case.
• FDA approved Ziextenzo on November 2, 2018.
• The parties settled in 2019, and the case was dismissed without a merits judgment.
• Sandoz commercialized Ziextenzo in the United States after the negotiated resolution.
• Amgen’s Neulasta estate included molecule, formulation, manufacturing, and method-of-use rights, but early foundational patents had expired or were approaching expiration.
• The settlement reduced immediate injunction risk for Sandoz and accelerated competitive pressure on Neulasta.
• No publicly reported decision established that Sandoz infringed a valid and enforceable Amgen patent.

FAQs About Amgen v. Sandoz and Ziextenzo

Did Amgen win the Neulasta lawsuit against Sandoz?

No final merits judgment was entered. The parties settled and the case was dismissed.

Was Ziextenzo an interchangeable biosimilar?

No. FDA approved Ziextenzo as a biosimilar to Neulasta, but not as an interchangeable biosimilar.

Did the case involve an Orange Book listing?

No. Neulasta is a biologic, and the dispute proceeded under the BPCIA rather than the Orange Book and Paragraph IV framework.

Did Sandoz pay Amgen to settle the case?

The publicly disclosed case materials did not report a payment amount or detailed financial terms. The settlement terms were substantially confidential.

Could Amgen sue other pegfilgrastim biosimilar manufacturers?

Yes. A settlement with Sandoz resolved the claims against Sandoz and did not automatically release other manufacturers from separate patent claims or future enforcement.

References

1. U.S. Food and Drug Administration. (2018, November 2). FDA approves first biosimilar pegfilgrastim to help reduce the risk of infection during cancer treatment. https://www.fda.gov/

2. Sandoz. (2019). Sandoz announces U.S. availability of Ziextenzo, the first FDA-approved biosimilar pegfilgrastim. Company announcement.

3. Amgen Inc. (2019). 2018 annual report. U.S. Securities and Exchange Commission.

4. Amgen Inc. v. Sandoz Inc., No. 3:18-cv-11026-MAS-DEA, U.S. District Court for the District of New Jersey.

5. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262(l).